Journal Article DKFZ-2018-01698

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.060

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2018
Springer-Verl. Heidelberg [u.a.]

European journal of nuclear medicine and molecular imaging 45(12), 2045 - 2054 () [10.1007/s00259-018-4079-z]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Since the introduction of PSMA PET/CT with 68Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings.A retrospective analysis was performed of all 1,704 patients who underwent a 68Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT.Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42-369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml).Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT.

Classification:

Contributing Institute(s):
  1. Radiologie (E010)
  2. Biostatistik (C060)
  3. Radiopharmazeutische Chemie (E030)
  4. KKE Nuklearmedizin (E060)
Research Program(s):
  1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2018
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > E010
Public records
Publications database

 Record created 2018-10-26, last modified 2024-02-29


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)